Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.

To identify novel targets for acute myeloid leukemia (AML) therapy, we performed genome-wide CRISPR-Cas9 screening using AML cell lines, followed by a second screen in vivo. Here, we show that the mRNA decapping enzyme scavenger (DCPS) gene is essential for AML cell survival. The DCPS enzyme interacted with components of pre-mRNA ...
metabolic pathways, including spliceosomes, as revealed by mass spectrometry. RG3039, a DCPS inhibitor originally developed to treat spinal muscular atrophy, exhibited anti-leukemic activity via inducing pre-mRNA mis-splicing. Humans harboring germline biallelic DCPS loss-of-function mutations do not exhibit aberrant hematologic phenotypes, indicating that DCPS is dispensable for human hematopoiesis. Our findings shed light on a pre-mRNA metabolic pathway and identify DCPS as a target for AML therapy.
Mesh Terms:
Animals, CRISPR-Cas Systems, Cell Line, Endoribonucleases, Humans, Leukemia, Male, Metabolic Networks and Pathways, Mice, Inbred C57BL, Muscular Atrophy, Spinal, Quinazolines, RNA Precursors, RNA Splicing, RNA, Messenger
Cancer Cell
Date: Dec. 12, 2017
Download Curated Data For This Publication
214519
Switch View:
  • Interactions 340